Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › insulin glargine

insulin glargine

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of insulin glargine

154 trials tracked of insulin glargine: 126 in phase 3 or 4 and 48 with published results. The most-cited published study has 652 citations.

154Trials tracked
126Phase 3 & 4
0Recruiting
48With published results
Phase distribution
Phase 4 38 Phase 3 88 Phase 2 13 Phase 1 11 Other / NA 4
  1. Phase 3 A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Completed · 652 cited
  2. Phase 3 A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events Completed · 574 cited
  3. Phase 3 Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes Completed · 461 cited
  4. Phase 3 A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Completed · 346 cited
  5. Phase 3 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine Completed · 253 cited
  6. Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes Completed · 222 cited
Show 44 more trials
  1. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Completed · 219 cited
  2. Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes Completed · 207 cited
  3. Phase 3 A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus Completed · 192 cited
  4. Phase 3 A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus Completed · 186 cited
  5. Phase 3 A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) Completed · 146 cited
  6. Phase 4 FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) Completed · 135 cited
  7. Phase 3 Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Completed · 120 cited
  8. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) Completed · 100 cited
  9. Phase 3 A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before Completed · 79 cited
  10. Phase 3 A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs Completed · 74 cited
  11. Phase 3 A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes Completed · 69 cited
  12. Phase 3 A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus Completed · 68 cited
  13. Phase 3 A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus Completed · 67 cited
  14. Phase 4 Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial) Completed · 53 cited
  15. Phase 4 Glargine Versus NPH in Patients With Chronic Kidney Disease Completed · 45 cited
  16. Phase 4 ADA Linagliptin in Long Term Care Completed · 43 cited
  17. Phase 3 A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification Completed · 41 cited
  18. Phase 4 Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga Completed · 33 cited
  19. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) Completed · 32 cited
  20. Phase 4 A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study Completed · 29 cited
  21. Phase 3 Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita) Completed · 23 cited
  22. Phase 3 A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes Completed · 20 cited
  23. Phase 3 Randomized Sitagliptin Withdrawal Study (MK-0431-845) Completed · 19 cited
  24. Phase 3 A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin Completed · 18 cited
  25. Phase 3 A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus Completed · 17 cited
  26. Phase 3 A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) Completed · 15 cited
  27. Phase 3 A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes Completed · 14 cited
  28. Phase 3 A Study of LY900014 in Participants With Type 1 Diabetes Completed · 14 cited
  29. Phase 3 The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006) Completed · 13 cited
  30. Phase 4 Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes Completed · 10 cited
  31. Phase 3 A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003) Completed · 9 cited
  32. Phase 4 A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients Completed · 8 cited
  33. Phase 4 Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. Completed · 6 cited
  34. Phase 4 Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings Completed · 5 cited
  35. Phase 3 A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) Completed · 5 cited
  36. Phase 3 A Study in Participants With Type 2 Diabetes Mellitus Completed · 5 cited
  37. Phase 3 Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus Completed · 4 cited
  38. Phase 3 Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2) Completed · 4 cited
  39. Phase 3 Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1) Completed · 4 cited
  40. Phase 3 A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Completed · 3 cited
  41. Phase 3 Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin Completed · 3 cited
  42. Phase 3 A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus Completed · 2 cited
  43. Phase 4 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients Completed
  44. Phase 4 The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes Completed

Showing the 50 most-cited and recently-updated of 154 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
IcoSema reduces HbA1c by 3.32 percentage points compared to 2.44 in type 2 diabetes
Diabetes & Endocrinology RCT
IcoSema reduces HbA1c by 3.32 percentage points compared to 2.44 in type 2 diabetes New weekly insulin combination shows better results for type 2 diabetes
This Phase 3b randomized trial of 485 adults with type 2 diabetes found that once-weekly IcoSema significantly reduced HbA1c by 3.32 percent…
A new once-weekly insulin combination helps people with type 2 diabetes lower their blood sugar and lose more weight.
Oct 3, 2026
Insulin degludec/liraglutide ranks highest for HbA1c reduction with SUCRA value of 89.4%
Nutrition & Obesity Medicine Sys. Review
Insulin degludec/liraglutide ranks highest for HbA1c reduction with SUCRA value of 89.4% Comparing Combination Diabetes Drugs for Blood Sugar Control
This network meta-analysis evaluated 12,815 patients with type 2 diabetes to compare fixed-ratio combination products and their individual c…
A review of 12,815 patients found that insulin degludec/liraglutide may be best for lowering blood sugar, but has more side effects than oth…
Jun 4, 2026
Sitagliptin and liraglutide superior for CGM targets in type 2 diabetes
Nutrition & Obesity Medicine RCT
Sitagliptin and liraglutide superior for CGM targets in type 2 diabetes Two diabetes drugs outperform others in long-term glucose control
This randomized trial compared adding sitagliptin, liraglutide, glimepiride, or insulin glargine to metformin in 1,080 participants with typ…
A five-year trial shows sitagliptin and liraglutide offer better glucose stability and safety than glimepiride or insulin glargine for peopl…
Diab Care Jun 1, 2026